To Explore the Efficacy of Sintilimab Combined With Bevacizumab in Rectal Cancer

To Explore the Efficacy of Sintilimab Combined With Bevacizumab in Rectal Cancer is a phase 2, interventional study registered as NCT06808412 by xiaohua li, with a registry enrolment figure of 118 participants, started 2024-07-05 and due to reach its primary completion in 2025-05-05. Interventions recorded: sintilimab combined with bevacizumab and XELOX. Conditions listed: Rcctal Cancer. Primary outcome: assess the pathological complete response (pCR) rate of tumors after neoadjuvant chemotherapy for rectal cancer using sintilimab combined with bevacizumab. Colorectal eligibility wording from the registry: "Rectal cancer patients who have previously received perioperative XELOX regimen treatment". Sites: China. No results are recorded here; the registry entry is the source.